Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Association of low‐level viremia with mortality among people living with HIV on antiretroviral therapy in Dehong, Southwest China: A retrospective cohort study

Association of low‐level viremia with mortality among people living with HIV on antiretroviral... INTRODUCTIONAntiretroviral therapy (ART) has dramatically reduced the viral load (VL) of the human immunodeficiency virus (HIV) and alleviated the damage to the immune system. Although the majority of people living with HIV (PLHIV) achieve viral suppression below the detectable limits (<50 copies/ml) within several months of ART [1,2], approximately 4–30% of infected individuals have a VL level remaining between 50 and 1000 copies/ml, the degree of virological failure defined by the World Health Organization (WHO) [3–5]. In other words, a low degree of VL is still detectable in this subset of PLHIV, an event referred to as low‐level viremia (LLV), usually defined as two or more consecutive HIV‐1 RNA values of 50–1000 copies/ml plus no levels consecutively higher than 1000 copies/ml according to guidelines used in other prior literature [6]. There is currently no consensus on how to define LLV. Different ART guidelines such as Department of Health and Human Services (DHHS) [1], International Antiviral Society [7] and Chinese Medical Association [8] (VL between 50 and 199 copies/ml defined as LLV) and WHO (between 50 and 1000 copies/ml) [5] collectively give different definitions for LLV.Based on existing cohort studies, the relationship between LLV and mortality is inconclusive. Bernal et http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png HIV Medicine Wiley

Association of low‐level viremia with mortality among people living with HIV on antiretroviral therapy in Dehong, Southwest China: A retrospective cohort study

Loading next page...
 
/lp/wiley/association-of-low-level-viremia-with-mortality-among-people-living-cAuf885LMs

References (28)

Publisher
Wiley
Copyright
© 2023 British HIV Association
ISSN
1464-2662
eISSN
1468-1293
DOI
10.1111/hiv.13320
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONAntiretroviral therapy (ART) has dramatically reduced the viral load (VL) of the human immunodeficiency virus (HIV) and alleviated the damage to the immune system. Although the majority of people living with HIV (PLHIV) achieve viral suppression below the detectable limits (<50 copies/ml) within several months of ART [1,2], approximately 4–30% of infected individuals have a VL level remaining between 50 and 1000 copies/ml, the degree of virological failure defined by the World Health Organization (WHO) [3–5]. In other words, a low degree of VL is still detectable in this subset of PLHIV, an event referred to as low‐level viremia (LLV), usually defined as two or more consecutive HIV‐1 RNA values of 50–1000 copies/ml plus no levels consecutively higher than 1000 copies/ml according to guidelines used in other prior literature [6]. There is currently no consensus on how to define LLV. Different ART guidelines such as Department of Health and Human Services (DHHS) [1], International Antiviral Society [7] and Chinese Medical Association [8] (VL between 50 and 199 copies/ml defined as LLV) and WHO (between 50 and 1000 copies/ml) [5] collectively give different definitions for LLV.Based on existing cohort studies, the relationship between LLV and mortality is inconclusive. Bernal et

Journal

HIV MedicineWiley

Published: Jan 1, 2023

Keywords: antiretroviral therapy; HIV; low‐level viremia; mortality; time‐dependent exposure

There are no references for this article.